| Literature DB >> 25852310 |
Dongquan Chen1, Todd A Stueckle2, Sudjit Luanpitpong3, Yon Rojanasakul3, Yongju Lu4, Liying Wang2.
Abstract
A rapid increase in utility of engineered nanomaterials, including carbon nanotubes (CNTs), has raised a concern over their safety. Based on recent evidence from animal studies, pulmonary exposure of CNTs may lead to nanoparticle accumulation in the deep lung without effective clearance which could interact with local lung cells for a long period of time. Physicochemical similarities of CNTs to asbestos fibers may contribute to their asbestos-like carcinogenic potential after long-term exposure, which has not been well addressed. More studies are needed to identify and predict the carcinogenic potential and mechanisms for promoting their safe use. Our previous study reported a long-term in vitro exposure model for CNT carcinogenicity and showed that 6-month sub-chronic exposure of single-walled carbon nanotubes (SWCNT) causes malignant transformation of human lung epithelial cells. In addition, the transformed cells induced tumor formation in mice and exhibited an apoptosis resistant phenotype, a key characteristic of cancer cells. Although the potential role of p53 in the transformation process was identified, the underlying mechanisms of oncogenesis remain largely undefined. Here, we further examined the gene expression profile by using genome microarrays to profile molecular mechanisms of SWCNT oncogenesis. Based on differentially expressed genes, possible mechanisms of SWCNT-associated apoptosis resistance and oncogenesis were identified, which included activation of pAkt/p53/Bcl-2 signaling axis, increased gene expression of Ras family for cell cycle control, Dsh-mediated Notch 1, and downregulation of apoptotic genes BAX and Noxa. Activated immune responses were among the major changes of biological function. Our findings shed light on potential molecular mechanisms and signaling pathways involved in SWCNT oncogenic potential.Entities:
Keywords: Gene expression; Lung; Microarray; Pathways; Single-walled carbon nanotubes; p53
Year: 2015 PMID: 25852310 PMCID: PMC4314466 DOI: 10.1186/s11671-014-0707-0
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Figure 1Hierarchical clustering of SWCNT-exposed and passage control cell gene expression following 6 months of continuous treatment. The hierarchical clustering was based on differentially expressed genes of SWCNT vs. control comparison using p < 0.05 and fold changes >2 criteria. Color indicates log2-transformed normalized intensities with red and blue indicating over- and underexpression, respectively.
Top biological processes changed after SWCNT treatment in transformed BEAS-2B cells compared to unexposed cells
|
|
|
|
|
|
|---|---|---|---|---|
| Response to metal ion | 8.6 | 0.000 | 37.5 | 10038 |
| Antigen processing and presentation of peptide antigen via MHC class I | 8.5 | 0.000 | 8.6 | 2474 |
| Regulation of circadian rhythm | 7.9 | 0.000 | 30 | 42752 |
| Antigen processing and presentation | 7.4 | 0.001 | 10.9 | 19882 |
| Positive regulation of microtubule depolymerization | 7.3 | 0.001 | 66.7 | 31117 |
| Regulation of phagocytosis | 7.3 | 0.001 | 66.7 | 50764 |
| Interspecies interaction between organisms | 7 | 0.001 | 4.2 | 44419 |
| Cellular chloride ion homeostasis | 6.6 | 0.001 | 50 | 30644 |
| Vacuolar transport | 6.6 | 0.001 | 50 | 7034 |
| Rhythmic process | 6.4 | 0.002 | 18.8 | 48511 |
The biological process was based on SWCNT vs. control comparison, p < 0.05 and fold changes >2.
Top molecular functions changed after SWCNT treatment in transformed BEAS-2B cells
|
|
|
|
|
|
|---|---|---|---|---|
| MHC class I receptor activity | 13.6 | 0.000 | 35.7 | 32393 |
| Flavonol 3-sulfotransferase activity | 7.3 | 0.001 | 66.7 | 47894 |
| Aryl sulfotransferase activity | 6.1 | 0.002 | 40.0 | 4062 |
| G-protein coupled photoreceptor activity | 6.1 | 0.002 | 40.0 | 8020 |
| SH3 domain binding | 6.1 | 0.002 | 5.8 | 17124 |
| Ubiquitin-specific protease activity | 5.7 | 0.003 | 9.8 | 4843 |
| Photoreceptor activity | 4.9 | 0.008 | 22.2 | 9881 |
| Protein binding | 4.7 | 0.009 | 1.9 | 5515 |
| Ubiquitin thiolesterase activity | 4.7 | 0.009 | 5.8 | 4221 |
| Cysteine-type endopeptidase activity | 4.5 | 0.011 | 6.9 | 4197 |
The molecular function was based on SWCNT vs. control comparison, p < 0.05 and fold changes >2.
Top affected gene-gene interaction networks after sub-chronic SWCNT exposure in transformed BEAS-2B cells
|
|
|
|
|
|---|---|---|---|
| Cellular growth and proliferation, hematological system development and function, humoral immune response | ADAM15, ADRBK2, ATP5B, BCL10, BCR (complex), CHGA, CR2, CRHR1, ERK1/2, FGR, GNAZ, HOPX, HSD11B2, HSPD1, HTATIP2, IgG1, Igg3, IgG2b, IGLL1/IGLL5, Igm, insulin, ITCH, Jnk, MFGE8, NEU1, PAK2, PAX4, PPP1R1B, Ras, RASGRP1, SH2B2, SH2D2A, TAS1R1, Vegf, ZNF24 | 35 | 25 |
| Connective tissue disorders, inflammatory disease, skeletal and muscular disorders | C1R, CD33, CD59, CDON, G6PD, HLA-A, HLA-B, HLA-C, HLA-E, Ifnar, IgG, IKK (complex), immunoglobulin, interferon alpha, KIR, KRT31, MYO1E, NFAT5, NFkB (complex), P38 MAPK, PI3K (family), PIM1, Pkc(s), RHOB, RNF34, RTKN, SCARB1, SIRPA, SLC6A6, Tap, TAPBP, TNFSF10, TRAF3IP2, USP11, USP18 | 33 | 24 |
| Cell death and survival, embryonic development, organismal development | ADAM17, AFF4, AKT2, Akt, AMPK, Ap1, BHLHE40, CD68, CELF1, CSNK1E, CSNK1G2, Cyclin A, DVL1, estrogen receptor, F actin, FMR1, GSK3B, HMGB3, HMGN5, Hsp70, IGFBP2, LCP1, LDL, MGLL, MUC4, OSGIN1, PDGF BB, PI3K (complex), PMAIP1, Ppp2c, PURA, SF3B3, STRN, USP6, USP33 | 33 | 24 |
| Cellular compromise, skeletal and muscular system development and function, post-translational modification | ARHGEF9, ATP13A2, CD3, Cg, Creb, CTSB, DUSP9, ERK, FBN1, FGF3, FSHR, GSTM4, Hdac, Histone h3, Histone h4, HSD17B1, IFI44, IFI44L, IgG2a, KDM3A, Lh, MCOLN1, MT1F, MT1X, NDRG1, NDRG4, NES, NPNT, ORAI1, OXT, PGK1, SOX12, STAT5a/b, STK17A, TCR | 33 | 24 |
| Cell morphology, cellular assembly and organization, cellular development | ACBD7, ADAM22, ANK1, AR, AS3MT, ATP5S, ATP6V0E2, ATP8B1, CACNA1E, CDC6, CHD8, DLG4, FARP1, GLUL, GPR182, GSTM1, HILPDA, HIST1H1A, IGF1R, KCNA4, KCNAB2, MCM8, NIPSNAP1, NUPR1, PPT2, RAB18, RCN2, SIPA1L1, SOX11, ST6GALNAC6, SYNGAP1, TEX2, TMEM30A, WNK1, ZSCAN16 | 21 | 18 |
| Respiratory system development and function, tissue morphology, cell cycle | 26 s Proteasome, ACTC1, ACTN1, ACTR2, ACTR3, BNIP3L, CAP2, CARD10, CKAP2, EBAG9, ELMOD3, ENC1, FAM89B, FSH, GEM, IGLL1/IGLL5, ING2, JMJD6, MED26, MT1L, NOL3, NR3C1, PRPH, PSMB1, RAB11A, RDM1, RNA polymerase II, SCAF8, SERTAD2, SFTPC, SIAH2, SMARCC1, TFDP2, TUBA4A, USP13 | 16 | 15 |
| Cancer, gastrointestinal disease, hepatic system disease | ACOT11, AHCY, ANXA7, ARL6IP1, ARNT, ASS1, AXIN1, AXIN2, BCLAF1, CAMLG, CCDC80, CYP1A1, EPHX1, FAM120A, FBXW7, HIST1H1C, IGFBP2, KAT5, KITLG, KREMEN2, MED13L, MT1H, N-cor, NCOR2, NQO1, PIAS2, PSMF1, PTGDS, PTP4A3, RBBP4, SERPINB6, SIDT2, STOX1, TCF7L2, TP53 | 16 | 15 |
| Cell morphology, cell-to-cell signaling and interaction, nervous system development and function | AIG1, ALDH3B1, C11orf30, CABYR, CACNA2D1, CHMP4B, COX10, CYFIP2, DGKZ, DMD, DNAJB6, DTNB, DYRK1A, HDAC4, HYOU1, INS, LEPR, Map4k4, MARK3, OPN4, Pdx1, PFKM, PPFIA1, proinsulin, SNCA, SNTB2, SPARC, SPOP, TNRC6B, TRIM44, TUBB4A, VEGFA, VGF, YWHAG, YWHAH | 16 | 15 |
| DNA replication, recombination, and repair, cellular compromise, cell death and survival | ATP6V0E1, BAG1, BAX, BGN, BRCA1, BRCA2, CCND1, CEL, CKB, DDX5, DNAJA1, DPYSL3, FANCD2, GATA1, GFI1B, GSK3A, H3F3A/H3F3B, Hbb-b2, HSPA4, HSPD1, LATS1, LINC00467, MAPT, NGFR, NME4, OPA1, ROCK2, SFN, SPOCK2, STIP1, TLE1, UBE2N, USP11, ZFPM1, ZNF324 | 15 | 14 |
| Lipid metabolism, molecular transport, small molecule biochemistry | AP1M2, APOA1, APOC1, ARCN1, CBS, CCL1, CCL22, CETP, CLIC4, COG3, COPG1, COPZ1, CXCL5, ERN1, EYA4, GSTA1, HLA-J, HYOU1, IFNB1, LCAT, MGLL, NPEPPS, Pdx1, PEX6, PHLDB2, PPARG, PTGES2, RGS14, RNASE1, TBXAS1, TMEM173, TNF, TPM2, Trim30a/Trim30d, XBP1 | 15 | 14 |
aThe network was based on SWCNT vs. control comparison, p < 0.05 and fold changes >2.
bCapitalized names indicate genes while lower case names indicate complexes.
cThe number of differentially expressed genes in each network are reported.
mRNA expressions of and related genes in SWCNT-transformed BEAS-2B cells
|
|
|
|
|
|
|---|---|---|---|---|
| A_23_P26810 | TP53 | Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) | 0.66 | −1.48 |
| A_24_P274842 | TP53AP1 | Homo sapiens mRNA for P53TG1-B, complete cds. | 0.75 | 1.26 |
| A_23_P145895 | TP53AP1 | Homo sapiens mRNA for P53TG1-C, complete cds. | 0.94 | 1.07 |
| A_23_P88703 | TP53BP1 | Homo sapiens tumor protein p53 binding protein, 1 | 0.70 | −1.21 |
| A_23_P12526 | TP53BP2 | Homo sapiens tumor protein p53 binding protein, 2, transcript variant 2 | 0.17 | −1.50 |
| A_23_P150281 | TP53I11 | Homo sapiens tumor protein p53 inducible protein 11 | 0.82 | −1.75 |
| A_24_P185207 | TP53I13 | Homo sapiens tumor protein p53 inducible protein 13 | 0.55 | 1.61 |
| A_24_P185205 | TP53I13 | Homo sapiens tumor protein p53 inducible protein 13 | 0.68 | 1.44 |
| A_23_P5392 | TP53I3 | Homo sapiens tumor protein p53 inducible protein 3, transcript variant 1 | 0.18 | 2.55 |
| A_23_P168882 | TP53INP1 | Homo sapiens tumor protein p53 inducible nuclear protein 1 | 0.10 | −4.86 |
| A_24_P357465 | TP53INP2 | Homo sapiens tumor protein p53 inducible nuclear protein 2 | 0.53 | −2.66 |
| A_24_P245646 | TP53RK | Homo sapiens TP53 regulating kinase | 0.60 | −1.33 |
| A_24_P227971 | TP53TG3 | Homo sapiens TP53TG3 protein | 0.65 | 1.50 |
| A_23_P49391 | TP53TG3 | Homo sapiens TP53TG3 protein | 0.95 | 1.07 |
Figure 2, , and -mediated alteration of p53 and β-catenin function in SWCNT transformed BEAS-2B cells. Color indicates upregulation (in red) and downregulation (in green). Protein assay (Figure 4) showed no significant level changes of Akt proteins and increased phosphorylated Akt indicating that activated Akt may play a role in Gsk3β inhibition of B-catenin and MDM2-mediated p53.
Figure 4pAkt, Akt, and Bcl-2 expression via SDS PAGE in B-Control and B-SWNCT transformed cells. pAkt, Akt, and Bcl-2 expression via SDS PAGE in B-Control and B-SWNCT transformed cells following 12 and 24 h re-exposure to dispersed SWCNT (1 to 50 μg/ml = 0.1 to 5.2 μg/cm2). β-actin was used as an internal loading control. (A) Representative blots are shown from three independent experiments. (B) pAkt/Akt ratio densitometry quantification. *indicates significant difference between the two cell types (p < 0.05). (C) Bcl-2 expression densitometry quantification. † indicates significant difference between B-SWCNT and B-Control at each time point (p < 0.05). *and # indicate significant difference of both B-Control and B-SWCNT cells, respectively, compared to its unexposed treatment group at 24 h (p < 0.05).
Figure 3Apoptosis protein expression array comparison of B-SWCNT to B-Control cells. Apoptosis protein expression array comparison of B-SWCNT to B-Control cells showed (A) altered Bcl-x, Xiap, Fas, TNFR1, claspin, and HSP60 expression in addition to three serine phosphorylation sites on p53 shown in our previous report [13]. (B) Densitometry quantification of protein array. Representative data are shown from two independent replicate experiments. See Additional file 1: Table S1 for array layout.